Literature DB >> 9627118

Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.

C J Di Como1, C Prives.   

Abstract

p53 is a sequence-specific transcriptional activator with a number of known target genes which contain p53-responsive elements. Mutations in p53 have been identified within its sequence-specific DNA binding domain in more than half of all human tumors, although a subset of tumor-derived p53 mutants have retained the ability to bind DNA and activate transcription under certain conditions. In order to broaden our understanding of this transactivating ability, we examined the efficacy by which p53 mutants bind to and activate reporters in an Saccharomyces cerevisiae-based assay. Analysis of 19 human tumor-derived p53 mutants, spanning the DNA binding domain of p53 and including the 'hot-spot' class, revealed a broad array of transcriptional transactivation abilities at 24 degrees C, 30 degrees C and 37 degrees C, despite the fact that each mutant had originally been identified as being inactive for transactivation in yeast against a single p53-responsive RGC site-containing reporter. One class of mutants (P177L, R267W, C277Y and R283H) retained wild-type or near wild-type activity that is binding site-selective, even at physiological temperature (37 degrees C). Another class of mutants (V143A, M1601/A161T, H193R, Y220C and 1254F), all positioned for maintaining the beta-scaffold of p53, also retained selective activity, but preferentially at sub-physiological temperatures (24 degrees and 30 degrees C). Strikingly, however, in contrast to the other tumor derived mutants, all of the previously identified 'hot-spot' mutants were completely inactive with all sites tested. Moreover, a double mutant, L22E/W23S, located within the activation region and previously shown to be transcriptionally inactive in fibroblasts, retained wild-type or near wild-type binding site-selective activity in yeast. Finally, we found that transcriptional activity in vivo does not necessarily correlate with DNA binding in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627118     DOI: 10.1038/sj.onc.1202041

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  Histone deacetylase-dependent transcriptional repression by pRB in yeast occurs independently of interaction through the LXCXE binding cleft.

Authors:  B K Kennedy; O W Liu; F A Dick; N Dyson; E Harlow; M Vidal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites.

Authors:  Ulrike Haugwitz; Mark Wasner; Marcus Wiedmann; Katja Spiesbach; Karen Rother; Joachim Mössner; Kurt Engeland
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

4.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

5.  Replication of damaged DNA in vitro is blocked by p53.

Authors:  Jianmin Zhou; Carol Prives
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

6.  Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Y M Yang; W H Lee; C G Lee; J An; E-S Kim; S H Kim; S-K Lee; C H Lee; D N Dhanasekaran; A Moon; S Hwang; S J Lee; J-W Park; K M Kim; S G Kim
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

7.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

8.  FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.

Authors:  Updesh Dixit; Ashutosh K Pandey; Zhihe Liu; Sushil Kumar; Matthew B Neiditch; Kenneth M Klein; Virendra N Pandey
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

9.  Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.

Authors:  A Nourani; Y Doyon; R T Utley; S Allard; W S Lane; J Côté
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

10.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.